Hopkins researchers recommend reclassifying psilocybin from schedule I to schedule IV
Because of its low potential for abuse and dependence, Hopkins researchers suggest recategorizing Psilocybin from “no known medical potential and high risk of abuse and dependence” (Schedule I) to “low potential for abuse and accepted medical use” (Schedule IV).
On a sidenote, Psilocybin also is lowest in the potential for lethal overdose as there is no known overdose level.
As for the time frame, Matthew W. Johnson, associate professor of psychiatry and behavioral sciences at the Johns Hopkins University School of Medicine states: “We expect these final clearance trials to take place in the next five years or so.”
Find the whole article on the John Hopkins University website here.